Drug Profile
Research programme: therapeutics targeting genomic alteration - Bayer HealthCare/Broad Institute/Harvard University
Alternative Names: cancer therapeutics - Bayer HealthCare/Broad Institute; cardiovascular disorder therapeutics - Bayer Healthcare/Broad Institute/Harvard UniversityLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer HealthCare; Broad Institute; Harvard University
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Cancer
- No development reported Cardiovascular disorders